A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals
Sponsor: Beatriz Mothe Pujadas PhD,MD
Listed as NCT05208125, this PHASE1 trial focuses on HIV Infection and remains completed. Sponsored by Beatriz Mothe Pujadas PhD,MD, it has been updated 10 times since 2022, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2024 — Jun 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Apr 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Apr 2023 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beatriz Mothe Pujadas PhD,MD
- IrsiCaixa
- José Moltó Marhuenda, PhD, MD
- Lucía Bailón Álvarez, MD
- Susana Benet Garrabé, PhD,MD
For direct contact, visit the study record on ClinicalTrials.gov .